Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The KRAS-G12C inhibitor: activity and resistance
Jiao Liu, Rui Kang, Daolin Tang
Cancer Gene Therapy (2021) Vol. 29, Iss. 7, pp. 875-878
Open Access | Times Cited: 130

Showing 1-25 of 130 citing articles:

Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance
Adnin Ashrafi, Zakia Akter, Pouya Modareszadeh, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4562-4562
Open Access | Times Cited: 68
Targeting KRAS: from metabolic regulation to cancer treatment
Yanyan Shi, Huiling Zheng, Tianzhen Wang, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 3
KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?
Sahar F. Bannoura, Husain Yar Khan, Asfar S. Azmi
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 61
Nanomedicine Combats Drug Resistance in Lung Cancer
Xiuli Zheng, Xiao-Hai Song, Guonian Zhu, et al.
Advanced Materials (2023) Vol. 36, Iss. 3
Closed Access | Times Cited: 35
Mechanisms of alkaliptosis
Fangquan Chen, Rui Kang, Jiao Liu, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 27
Design, synthesis and biological evaluation of KRASG12C-PROTACs
Xiaoyi Zhang, Tong Zhao, Minghao Sun, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 78, pp. 117153-117153
Closed Access | Times Cited: 24
In vivo CRISPR screens reveal Serpinb9 and Adam2 as regulators of immune therapy response in lung cancer
Dzana Dervovic, Ahmad Malik, Edward L. Y. Chen, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 22
The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC
Firas Batrash, Mahmoud Kutmah, Jun Zhang
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 22
Targeting paraptosis in cancer: opportunities and challenges
Fangquan Chen, Hu Tang, Xiutao Cai, et al.
Cancer Gene Therapy (2024) Vol. 31, Iss. 3, pp. 349-363
Open Access | Times Cited: 11
Hepatobiliary Adverse Events Associated With the KRAS p.G12C Inhibitor Sotorasib
Connor Frey
Pharmacoepidemiology and Drug Safety (2025) Vol. 34, Iss. 2
Open Access | Times Cited: 1
Resistance looms for KRAS G12C inhibitors and rational tackling strategies
Junmin Zhang, Jilei Zhang, Qing Liu, et al.
Pharmacology & Therapeutics (2021) Vol. 229, pp. 108050-108050
Closed Access | Times Cited: 44
FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021
Aleksandra Sochacka-Ćwikła, Marcin Mą̨czyński, Andrzej Regiec
Molecules (2022) Vol. 27, Iss. 7, pp. 2259-2259
Open Access | Times Cited: 31
Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer
Marwan Fakih, Huakang Tu, Hil Hsu, et al.
The Oncologist (2022) Vol. 27, Iss. 8, pp. 663-674
Open Access | Times Cited: 30
Glimmers of hope for targeting oncogenic KRAS-G12D
Daolin Tang, Rui Kang
Cancer Gene Therapy (2022)
Open Access | Times Cited: 29
Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review
John H. Strickler, Takayuki Yoshino, Kendall Stevinson, et al.
The Oncologist (2023) Vol. 28, Iss. 11, pp. e981-e994
Open Access | Times Cited: 19
Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure
Victor Hugo Fonseca de Jesus, Maria Cecília Mathias-Machado, João Paulo Fogacci de Farias, et al.
Cancers (2023) Vol. 15, Iss. 20, pp. 5015-5015
Open Access | Times Cited: 17
Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS -mutant cancers
Robin A. Jansen, Sara Mainardi, Matheus Henrique Dias, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 9
Open Access | Times Cited: 6
Conformational Dynamics Allows Sampling of an “Active-like” State by Oncogenic K-Ras-GDP
Patrick Grudzien, Hyunbum Jang, Nicholas Leschinsky, et al.
Journal of Molecular Biology (2022) Vol. 434, Iss. 17, pp. 167695-167695
Open Access | Times Cited: 24
Combined KRASG12Cand SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance
Venu Thatikonda, Hengyu Lu, Sabine Jurado, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 14
Human Cytochrome P450 1, 2, 3 Families as Pharmacogenes with Emphases on Their Antimalarial and Antituberculosis Drugs and Prevalent African Alleles
Chiratidzo R. Chamboko, Wayde Veldman, Rolland Bantar Tata, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3383-3383
Open Access | Times Cited: 14
Identification of Dietary Bioflavonoids as Potential Inhibitors against KRAS G12D Mutant—Novel Insights from Computer-Aided Drug Discovery
Prasanna Srinivasan Ramalingam, Purushothaman Balakrishnan, Senthilnathan Rajendran, et al.
Current Issues in Molecular Biology (2023) Vol. 45, Iss. 3, pp. 2136-2156
Open Access | Times Cited: 14
UHRF1 is a mediator of KRAS driven oncogenesis in lung adenocarcinoma
Kaja Kostyrko, Marta Román, Alex G. Lee, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 14
Initiation of Cancer: The Journey From Mutations in Somatic Cells to Epigenetic Changes in Tissue-resident VSELs
Deepa Bhartiya, Sherif Raouf, Kshama Pansare, et al.
Stem Cell Reviews and Reports (2024) Vol. 20, Iss. 4, pp. 857-880
Closed Access | Times Cited: 5
Activity and resistance to KRASG12C inhibitors in non-small cell lung cancer and colorectal cancer
Wei Ye, Lu Xin, Yue Qiao, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 3, pp. 189108-189108
Closed Access | Times Cited: 5
Driver Mutations in Pancreatic Cancer and Opportunities for Targeted Therapy
Olamide Tosin Olaoba, Temitope Isaac Adelusi, Ming Yang, et al.
Cancers (2024) Vol. 16, Iss. 10, pp. 1808-1808
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top